Eli Lilly Shares Approach High as 60% Volume Surge Offsets 13% Price Fall

Eli Lilly and Company finished Tuesday at $1,225.73, standing 1.9% under its highest level. The stock rose 3.6% as investors responded to the pharmaceutical firm's ongoing earnings strength.

19 August 2026

Novo Nordisk Shares (NYSE:NVO) Gain 1.9% as $50 Medicare Wegovy Access Trial Challenges Pricing

Novo Nordisk A/S advanced 1.85% to $45.71 on Tuesday, with renewed investor attention on semaglutide coverage. The close exceeded the S&P 500's performance by 2.54 percentage points. Eli Lilly and Company finished up 3.60%.

19 August 2026

NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk Stock’s Raised Outlook Leaves Just 2% Consensus Upside

Novo Nordisk shares lost 2.9% last week, closing Friday at $45.89. The decline came after management raised its 2026 outlook on August 4. That gap is the clearest signal for investors: better near-term execution has not yet settled the longer-term growth debate.

16 August 2026

Earnings·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen

Novo Nordisk shares (CPH:NOVO-B; NYSE:NVO) drop 4% after cost-driven profit outpaces forecasts but Wegovy concerns persist

COPENHAGEN, August 5, 2026, 10:26 CEST — Novo Nordisk saw its stock decline by 4% as the company's profit, which surpassed estimates due to reduced costs, did not fully address ongoing uncertainties over its Wegovy product.

5 August 2026

Earnings·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen

Novo Nordisk’s U.S. ADR dropped 6.8% on Tuesday even after the company reported earnings that surpassed expectations. The decline indicates lingering investor doubts about the strength of its recovery.

4 August 2026

Earnings·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance

Shares of Novo Nordisk A/S dropped significantly on Friday after the ZEUS trial found minimal cardiovascular benefit from ziltivekimab. The decline in U.S. trading wiped out approximately $20.5 billion in market capitalisation.

31 July 2026

CPH:NOVO-B·Earnings·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk (CPH:NOVO-B) gains as South Africa copycat order tops Ozempic, Wegovy local sales

Novo Nordisk’s B shares jumped 2.6% to 307.75 Danish crowns on Tuesday. The stock is up 5.1% since Friday’s close and has gained 9.9% over three sessions. The OMXC25 index in Copenhagen fell 0.07%.

24 June 2026

NYSE:CVS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause

Veru Inc. shares stayed active premarket Friday as the biotech said it has a supply deal with Novo Nordisk tied to a weight-loss study using Wegovy. Benzinga data had the stock at $3.70 before the open at 7:01 a.m. ET. The move followed Thursday’s rally, when it closed at $4.23, up 88% for the day.

5 June 2026

NASDAQ:VERU·NYSE:NVO·Pharmaceuticals·Stock Market

Veru shares jump after Novo Nordisk deal draws traders

Veru Inc. shares jumped over 100% Thursday. The small-cap biotech said it's got a clinical supply deal with Novo Nordisk for its obesity trial. That puts a major drugmaker next to one of the more speculative weight-loss names in the market.

4 June 2026

NASDAQ:VERU·NYSE:NVO·Stock Market

Novo Nordisk Shares Rise As Ozempic Study Shows 15% Weight Loss In Older Adults

Novo Nordisk A/S picked up new backing for its obesity lineup Monday, as a pooled analysis from the STEP trials found semaglutide produced significant weight loss among adults 65 and up—a population where physicians typically tread carefully due to frailty and complex health profiles.

11 May 2026

NYSE:NVO·Pharmaceuticals

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Investors eye Hims & Hers Health Inc. as it approaches Monday’s first-quarter results, with attention locked on the future of its weight-loss segment—especially after the company pulled back from widely promoted compounded GLP-1 drugs. Earnings will post after the U.S. markets close, followed by a 5 p.m. ET conference call, according to Hims & Hers.

11 May 2026

Earnings·NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk bumped up its 2026 forecast on Wednesday, buoyed by stronger-than-expected initial sales for its Wegovy weight-loss pill—a fresh win in its rivalry with Eli Lilly. In Copenhagen, the stock jumped up to 9.2% after Novo told investors it now expects this year’s drops in sales and profit to be less steep than it previously warned.

6 May 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Prescriptions for Eli Lilly and Company’s new oral weight-loss drug Foundayo reached 3,707 in the U.S. during its second week, according to IQVIA data cited by analysts. That’s behind the early numbers seen for Novo Nordisk’s competing Wegovy pill and has weighed on Lilly shares. In its launch week, Foundayo saw 1,390 prescriptions.

24 April 2026

Health News·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk A/S’s Wegovy pill stayed ahead in the early going, with 18,410 U.S. prescriptions at the same stage of launch where Eli Lilly’s Foundayo managed 3,707 in its second week, according to analysts referencing IQVIA data. RBC Capital Markets analyst Trung Huynh flagged that it’s early days and comparisons can be tricky, but noted that Foundayo’s latest numbers are likely to be viewed as a disappointment.

24 April 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health announced Thursday that its providers are now able to send prescriptions for Eli Lilly’s Zepbound vials, the Zepbound KwikPen, and the Foundayo pill directly to LillyDirect. With this move, the telehealth company is expanding its reach into branded obesity treatments. The company said that, combined with its previous Novo Nordisk partnership, it now offers what it describes as the full lineup of FDA-approved GLP-1 drugs on its platform.

23 April 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health dropped 1.6% to $30.52 in afternoon trading Tuesday, sliding after Amazon rolled out a GLP-1 weight-management program via One Medical. Shares, which opened at $28.31 and touched a session low of $28.01, took a hit as the telehealth firm faces increased heat to revamp its weight-loss segment.

21 April 2026

NASDAQ:AMZN·NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket action as of 9:00 a.m. EDT on Thursday, following a 10.3% jump to $25.88 at Wednesday’s close. That put the telehealth company on track for its fourth consecutive advance.

12 March 2026

NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Stock Market

Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Health shares surged 5.9% to finish at $23.47 on Tuesday, building on a two-day rally that’s now hit roughly 49%. The telehealth firm had closed at $15.74 back on March 6, then soared to $22.16 at Monday’s close. During Tuesday’s session, the stock swung from $22.43 up to $26.03 before easing back to settle below its session peak, following news of a fresh distribution deal with Novo Nordisk.

11 March 2026

NASDAQ:HIMS·NYSE:NVO·Stock Market

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.

10 March 2026

Health News·NYSE:ABBV·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly and Company shares slipped 2.3% to $1,028.07 in Monday afternoon trading. Earlier in the session, the stock climbed as high as $1,056.84 but also dropped to $1,023.50 at its lowest. The drugmaker now holds a market value near $686 billion.

2 March 2026

HKG:1801·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

1 2 3 … 8 Next